ACADIA PHARMACEUTICALS INC. Temporary Equity, Redemption Value (Deprecated 2014-01-31)
ACADIA PHARMACEUTICALS INC. (ACAD) had Temporary Equity, Redemption Value (Deprecated 2014-01-31) of $10.66 million as of 2013-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Notes
us-gaap:TemporaryEquityRedemptionValue · last filed 2014-02-27
- 2013-09-30: Temporary Equity, Redemption Value (Deprecated 2014-01-31) $10.66M.
- 2013-06-30: Temporary Equity, Redemption Value (Deprecated 2014-01-31) $17.66M.
- 2012-12-31: Temporary Equity, Redemption Value (Deprecated 2014-01-31) $17.66M.
| Period end | Temporary Equity, Redemption Value (Deprecated 2014-01-31) |
|---|---|
| 2013-09-30 | $10.66M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $17.66M 10-Q · filed 2013-08-06 |
| 2012-12-31 | $17.66M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |